¶ Intermediolateral Cell Column (IML) Neurons
Intermediolateral Cell Column Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The Intermediolateral Cell Column (IML) is a prominent column of sympathetic preganglionic neurons located in the lateral horn of the spinal cord. These neurons form the central component of the sympathetic nervous system, controlling involuntary functions that maintain homeostasis. The IML is critically important in neurodegenerative diseases, particularly Multiple System Atrophy (MSA), where autonomic failure is a hallmark feature.
¶ Location and Structure
The IML extends from the first thoracic segment (T1) to the second lumbar segment (L2), corresponding to the spinal cord segments that give rise to sympathetic outflow to the body. The column is positioned in the lateral horn of the spinal cord gray matter, specifically within lamina VII and portions of lamina IX.
Key anatomical features include:
- Rostral-caudal extent: T1-L2 spinal segments
- Cell density: Highest in thoracic segments T2-T6
- Column width: 1-3 neurons thick
- Dendritic architecture: Extensive dendritic arborization allowing integration of visceral and somatic inputs
The IML contains several distinct neuronal populations:
-
Sympathetic Preganglionic Neurons (SPNs): The primary neuronal type, accounting for approximately 80% of IML neurons
- Pethoracic (visceral) SPNs: Target visceral organs
- Lumbar (somatic) SPNs: Target sympathetic chain ganglia
-
Interneurons: Local circuit neurons that modulate SPN activity
- Excitatory interneurons using glutamate
- Inhibitory interneurons using GABA/glycine
-
Presympathetic neurons: Neurons that project to sympathetic premotor centers in the brainstem
| Marker |
Expression |
Significance |
| ChAT |
High |
Acetylcholine synthesis |
| Phox2b |
High |
Transcription factor, specifies sympathetic lineage |
| Islet1 |
High |
Transcription factor |
| Nkx2-2 |
Subset |
Specification factor |
| NOS |
Subset |
Nitric oxide synthesis |
| Catecholaminergic enzymes |
Subset |
Tyrosine hydroxylase expression |
The IML serves as the final common pathway for sympathetic nervous system output, controlling:
Cardiovascular Function
- Heart rate regulation through cardiac sympathetic innervation
- Vasoconstriction of blood vessels
- Blood pressure maintenance
- Cardiac contractility modulation
Thermoregulation
- Sweating (sudomotor function)
- Cutaneous vasoconstriction
- Thermogenic responses (brown adipose tissue)
Pupillary Function
- Pupillary dilation (mydriasis) via superior cervical ganglion
- Eye position adjustments
Visceral Organ Control
- Bronchodilation
- Gastrointestinal motility inhibition
- Urinary bladder relaxation
- Sexual organ function
The IML receives and integrates multiple input streams:
- Visceral afferents: From internal organs via vagus and pelvic nerves
- Somatic afferents: From body wall and limbs
- Supraspinal inputs: From hypothalamus, medulla, and pons
- Spinal interneuronal inputs: Local processing circuits
This integration allows coordinated sympathetic responses to environmental and internal challenges.
MSA is a prototypical neurodegenerative disease affecting the IML:
- Pathology: Oligodendroglial α-synuclein inclusions (GCIs)
- Cellular vulnerability: Loss of preganglionic sympathetic neurons
- Clinical manifestations: Orthostatic hypotension, urinary dysfunction, anhidrosis
- Neuroimaging: Reduced IML signal intensity on MRI
The selective vulnerability of IML neurons in MSA reflects their unique neurobiological properties:
- High metabolic demand
- Long axons requiring efficient transport
- Specific protein expression patterns
While primarily affecting dopaminergic neurons, PD involves autonomic dysfunction:
- α-Synuclein pathology: May affect IML neurons
- Autonomic symptoms: Orthostatic hypotension, constipation, urinary dysfunction
- Treatment effects: Levodopa may worsen orthostatic hypotension
Traumatic or ischemic spinal cord injury above T6 disrupts IML function:
- Autonomic dysreflexia: Uncontrolled hypertensive episodes
- Neurogenic shock: Loss of sympathetic tone
- Temperature dysregulation: Inability to sweat below injury level
Damage to sympathetic pathways including IML results in:
- Ptosis (drooping eyelid)
- Miosis (constricted pupil)
- Anhidrosis (loss of sweating)
- Enophthalmos (sunken eye)
IML neurons exhibit specific vulnerability factors:
- Long axonal projections: Require efficient axonal transport
- High metabolic demand: Continuous autonomic output
- Calcium dysregulation: Voltage-gated calcium channel expression
- Mitochondrial dependence: High energy requirements
- Protein aggregation susceptibility: α-Synuclein expression
- Apoptosis: Programmed cell death
- Excitotoxicity: Glutamate-induced damage
- Oxidative stress: Reactive oxygen species accumulation
- Neuroinflammation: Glial activation
- Axonal degeneration: Dying-back neuropathy
| Drug Class |
Target |
Application |
| Midodrine |
α1-adrenergic receptors |
Orthostatic hypotension |
| Fludrocortisone |
Mineralocorticoid receptors |
Volume expansion |
| Pyridostigmine |
Cholinesterase |
Autonomic function |
| Droxidopa |
Norepinephrine precursor |
Neurogenic hypotension |
- Gene therapy: Vector delivery of neurotrophic factors
- Cell transplantation: Autologous stem cell-derived neurons
- Neuroprotective compounds: Targeting specific death pathways
- Immunotherapy: α-Synuclein-targeted approaches
- Blood pressure management: Compression stockings, salt intake
- Bladder training: Intermittent catheterization
- Temperature regulation: Environmental modifications
- Rehabilitation: Autonomic training programs
- Rodent IML: Anatomical and physiological characterization
- Transgenic models: α-Synuclein overexpression
- ** lesion models**: 6-OHDAO lesion studies
- iPSC-derived sympathetic neurons: Patient-specific models
- Organoid systems: Autonomic neuron differentiation
- Co-culture models: Neuron-glia interactions
Intermediolateral Cell Column Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Intermediolateral Cell Column Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Strack AM, Sawyer WB, Platt KB, Loewy AD. Organization of sympathetic preganglionic neurons in the spinal cord. J Comp Neurol. 1988;272(4):560-582
- Benarroch EE. Autonomic nervous system and sleep. Continuum (Minneap Minn). 2015;21(3):690-707
- Wenning GK, Stankovic I, Vignatelli L. Multiple system atrophy: clinicopathological characteristics and neuroimaging. J Neural Transm (Vienna). 2021;128(11):1573-1587
- Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912
- Furlan JC, Fehlings MG. Cardiovascular complications after acute spinal cord injury: pathophysiology, clinical manifestations, and management. J Neurosurg Spine. 2008;8(1):81-92
- Jellinger KA. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord. 2014;29(14):1724-1741
- Benarroch EE. Autonomic failure in neurodegenerative disorders. Semin Neurol. 2007;27(4):330-337